Regueiro M., Swoger J. Clinical Challenges and Complications Of IBD. Thorofare; 2013.
Kim M., Choi K.H., Hwang S.W., Lee Y.B., Park HJ., Bae J.M. inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: A population-based cross-sectional study. J Am Acad Dermatol. 2017;76(1):40-48. doi: 10.1016/j.jaad.2016.08.022..
DOI: 10.1016/j.jaad.2016.08.022
Greuter T., Navarini A., Vavricka S.R. Skin Manifestations of inflammatory Bowel Disease. Clin Rev Allergy Immunol. 2017;53(3):413-427. doi: 10.1007/s12016-017-8617-4..
DOI: 10.1007/s12016-017-8617-4
Suh H.Y., Lee WJ., Na S.Y Dermatologic Manifestations in inflammatory Bowel Disease. Korean J Gastroenterol. 2019;73(5):285-293. doi: 10.4166/kjg.2019.73.5.285..
DOI: 10.4166/kjg.2019.73.5.285
Masaki S., Bayaraa B., imafuku S. Prevalence of inflammatory bowel disease in Japanese psoriatic patients. J Dermatol. 2019;46(7):590-594. doi: 10.1111/1346-8138.14900..
DOI: 10.1111/1346-8138.14900
Leung A.K.C., Leong K.F., Lam J.M. Erythema nodosum. World J Pediatr. 2018;14(6):548-554. doi: 10.1007/s12519-018-0191-1..
DOI: 10.1007/s12519-018-0191-1
Singh B., Kedia S., Konijeti G., Mouli V.P., Dhingra R., Kurrey L., Srivastava S., Pradhan R., Makharia G., Ahuja V. Extraintestinal manifestations of inflammatory bowel disease and intestinal tuberculosis: Frequency and relation with disease phenotype. Indian J Gastroenterol. 2015;34(1):43-50. doi: 10.1007/s12664-015-0538-7..
DOI: 10.1007/s12664-015-0538-7
Адаскевич В.П., Мяделец О.Д. Дерматозы эозинофильные и нейтро-фильные. М.: Медицинская книга; 2001. Режим доступа: https://search.rsl. ru/ru/record/01000710672.https://search.rsl
Адаскевич В.П., Мяделец О.Д. Дерматозы эозинофильные и нейтро-фильные. М.: Медицинская книга; 2001. Режим доступа: https://search.rsl. ru/ru/record/01000710672.https://search.rsl.ru/ru/record/01000710672
Tian Y., Li J.X., Wang H.H., Li R.Y., Liu X.G. Clinical analysis of cutaneous manifestations and related factors in patients with ulcerative colitis. Zhonghua Nei Ke Za Zhi. 2016;55(7):505-509. doi: 10.3760/cma.j.issn.0578-1426.2016.07.004..
DOI: 10.3760/cma.j.issn.0578-1426.2016.07.004https://search.rsl.ru/ru/record/01000710672
Vavricka S.R., Galvan JA., Dawson H., Soltermann A., Biedermann L., Scharl M., Schoepfer A.M., Rogler G., Prinz Vavricka M.B., Terracciano L., Navarini A., Zlobec I., Lugli A., Greuter T. Expression Patterns of TNFa, MAdCAM1, and STAT3 in intestinal and Skin Manifestations of inflammatory Bowel Disease. J Crohns Colitis. 2018;12(3):347-354. doi: 10.1093/ecco-jcc/jjx158..
DOI: 10.1093/ecco-jcc/jjx158
Vavricka S.R., Galvan JA., Dawson H., Soltermann A., Biedermann L., Scharl M., Schoepfer A.M., Rogler G., Prinz Vavricka M.B., Terracciano L., Navarini A., Zlobec I., Lugli A., Greuter T. Expression Patterns of TNFa, MAdCAM1, and STAT3 in intestinal and Skin Manifestations of inflammatory Bowel Disease. J Crohns Colitis. 2018;12(3):347-354. doi: 10.1093/ecco-jcc/jjx158..
DOI: 10.3760/cma.j.issn.0578-1426.2016.07.004
Fleisher M., Marsal J., Lee S.D., Frado L.E., Parian A., Korelitz B.i., Feagan B.G. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in inflammatory Bowel Disease. Dig Dis Sci. 2018;63(4):825-833. doi: 10.1007/s10620-018-4971-1..
DOI: 10.1007/s10620-018-4971-1
Fleisher M., Marsal J., Lee S.D., Frado L.E., Parian A., Korelitz B.i., Feagan B.G. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in inflammatory Bowel Disease. Dig Dis Sci. 2018;63(4):825-833. doi: 10.1007/s10620-018-4971-1..
DOI: 10.3760/cma.j.issn.0578-1426.2016.07.004
Dubinsky M.C., Cross R.K., Sandborn WJ., Long M., Song X., Shi N. et al. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(9):1876-1882. doi: 10.1093/iBD/izy065..
DOI: 10.1093/iBD/izy065
Dubinsky M.C., Cross R.K., Sandborn WJ., Long M., Song X., Shi N. et al. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(9):1876-1882. doi: 10.1093/iBD/izy065..
DOI: 10.1093/ecco-jcc/jjx158
Jellali K., Mellouki i., ibrahimi A. Cheilitis granulomatosa revealing Crohn's disease. Pan Afr Med J. 2018;30:147. doi: 10.11604/pamj.2018.30.147.5395..
DOI: 10.11604/pamj.2018.30.147.5395
Jellali K., Mellouki i., ibrahimi A. Cheilitis granulomatosa revealing Crohn's disease. Pan Afr Med J. 2018;30:147. doi: 10.11604/pamj.2018.30.147.5395..
DOI: 10.1093/ecco-jcc/jjx158
Lukach AJ., Saul M.i., Ferris L.K., Swoger J.M. Risk Factors for Hidradenitis Suppurativa in Patients with inflammatory Bowel Disease. Dig Dis Sci. 2018;63(3):755-760. doi: 10.1007/s10620-018-4919-5..
DOI: 10.1007/s10620-018-4919-5
Lukach AJ., Saul M.i., Ferris L.K., Swoger J.M. Risk Factors for Hidradenitis Suppurativa in Patients with inflammatory Bowel Disease. Dig Dis Sci. 2018;63(3):755-760. doi: 10.1007/s10620-018-4919-5..
DOI: 10.1007/s10620-018-4971-1
Yadav S., Singh S., Edakkanambeth Varayil J., Harmsen W.S., Zinsmeister A.R., Tremaine WJ. et al. Hidradenitis Suppurativa in Patients with inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2016;14(l):65-70. doi: 10.1016/j.cgh.2015.04.173..
DOI: 10.1016/j.cgh.2015.04.173
Yadav S., Singh S., Edakkanambeth Varayil J., Harmsen W.S., Zinsmeister A.R., Tremaine WJ. et al. Hidradenitis Suppurativa in Patients with inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2016;14(l):65-70. doi: 10.1016/j.cgh.2015.04.173..
DOI: 10.1007/s10620-018-4971-1
McNally A., Ibbetson J., Sidhu S. Azathioprine-induced Sweet's syndrome: A case series and review of the literature. Australas J Dermatol. 2017;58(1):53-57. doi: 10.1111/ajd.12383..
DOI: 10.1111/ajd.12383
McNally A., Ibbetson J., Sidhu S. Azathioprine-induced Sweet's syndrome: A case series and review of the literature. Australas J Dermatol. 2017;58(1):53-57. doi: 10.1111/ajd.12383..
DOI: 10.1093/IBD/izy065
Pietrzak D., Pietrzak A., Krasowska D., Borzęcki A., Franciszkiewicz-Pietrzak K., Polkowska-Pruszyńska B., Baranowska M., Reich K. Digestive system in psoriasis: an update. Arch Dermatol Res. 2017; 309(9):679-693. doi: 10.1007/s00403-017-1775-7..
DOI: 10.1007/s00403-017-1775-7
Pietrzak D., Pietrzak A., Krasowska D., Borzęcki A., Franciszkiewicz-Pietrzak K., Polkowska-Pruszyńska B., Baranowska M., Reich K. Digestive system in psoriasis: an update. Arch Dermatol Res. 2017; 309(9):679-693. doi: 10.1007/s00403-017-1775-7..
DOI: 10.1093/IBD/izy065
Lolli E., Saraceno R., Calabrese E., Ascolani M., Scarozza P., Chiricozzi A. et al. Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study. J Crohns Colitis. 2015;9(9):699-707. doi: 10.1093/ECCO-0KK/jjv068..
DOI: 10.1093/ECCO-0KK/jjv068
Lolli E., Saraceno R., Calabrese E., Ascolani M., Scarozza P., Chiricozzi A. et al. Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study. J Crohns Colitis. 2015;9(9):699-707. doi: 10.1093/ECCO-0KK/jjv068..
DOI: 10.11604/pamj.2018.30.147.5395
Cottone M., Sapienza C., Macaluso F.S., Cannizzaro M. Psoriasis and Inflammatory Bowel Disease. Dig Dis. 2019;37(6):451-457. doi: 10.1159/000500116..
DOI: 10.1159/000500116
Cottone M., Sapienza C., Macaluso F.S., Cannizzaro M. Psoriasis and Inflammatory Bowel Disease. Dig Dis. 2019;37(6):451-457. doi: 10.1159/000500116..
DOI: 10.11604/pamj.2018.30.147.5395
Яблокова Е.А., Горелов А.В., Шевцова ГВ., Полотнянко Е.Ю., Граммотопуло М.И., Борисова Е.В., Каншина АА. Внекишечные проявления воспалительных заболеваний кишечника у детей. Вопросы практической педиатрии. 2015;3(10):65-74. Режим доступа: http://www.phdynasty.ru/katalog/zhurnaly/voprosy-prakticheskoy-pediatrii/2015/tom-10-nomer-3/24553..
DOI: 10.1007/s10620-018-4919-5http://www.phdynasty.ru/katalog/zhurnaly/voprosy-prakticheskoy-pediatrii/2015/tom-10-nomer-3/24553
Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А., Знаменская Л.Ф., Коротаева Т.В., Круглова Л.С. и др. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности воспалительного процесса, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Альманах клинической медицины. 2018;46(5):426-444. doi: 10.18786/2072-0505-2018-46-5-426-444..
DOI: 10.18786/2072-0505-2018-46-5-426-444
Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А., Знаменская Л.Ф., Коротаева Т.В., Круглова Л.С. и др. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности воспалительного процесса, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Альманах клинической медицины. 2018;46(5):426-444. doi: 10.18786/2072-0505-2018-46-5-426-444..
DOI: 10.1007/s10620-018-4919-5
Hindryckx P, Novak G., Costanzo A., Danese S. Disease-related and drug-induced skin manifestations in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 201711(3)203-214. doi: 10.1080/17474124.2017.1283985..
DOI: 10.1080/17474124.2017.1283985
Hindryckx P, Novak G., Costanzo A., Danese S. Disease-related and drug-induced skin manifestations in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 201711(3)203-214. doi: 10.1080/17474124.2017.1283985..
DOI: 10.1016/j.cgh.2015.04.173
Pugliese D., Daperno M., Fiorino G., Savarino E., Mosso E., Biancone L. et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Dig Liver Dis. 2019;51(7):972-977. doi: 10.1016/j.dld.2019.03.007..
DOI: 10.1016/j.dld.2019.03.007
Pugliese D., Daperno M., Fiorino G., Savarino E., Mosso E., Biancone L. et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Dig Liver Dis. 2019;51(7):972-977. doi: 10.1016/j.dld.2019.03.007..
DOI: 10.1016/j.cgh.2015.04.173
Sanchez-Martinez M.A., Garcia-Planella E., Laiz A., Puig L. Inflammatory Bowel Disease: Joint Management in Gastroenterology and Dermatology. Actas Dermosifiliogr. 2017;108(3):184-191. doi: 10.1016/j.ad.2016.07.007..
DOI: 10.1016/j.ad.2016.07.007
Sanchez-Martinez M.A., Garcia-Planella E., Laiz A., Puig L. Inflammatory Bowel Disease: Joint Management in Gastroenterology and Dermatology. Actas Dermosifiliogr. 2017;108(3):184-191. doi: 10.1016/j.ad.2016.07.007..
DOI: 10.1111/ajd.12383
Vedak P, Kroshinsky D., St John J., Xavier RJ., Yajnik V., Ananthakrishnan A.N. Genetic basis of TNF-a antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis. Aliment Pharmacol Ther. 2016;43(6):697-704. doi: 10.1111/apt.13542..
DOI: 10.1111/apt.13542
Vedak P, Kroshinsky D., St John J., Xavier RJ., Yajnik V., Ananthakrishnan A.N. Genetic basis of TNF-a antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis. Aliment Pharmacol Ther. 2016;43(6):697-704. doi: 10.1111/apt.13542..
DOI: 10.1111/ajd.12383
Pugliese D., Guidi L., Ferraro P.M., Marzo M., Felice C., Celleno L. et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015; 42(7):880-888. doi: 10.1111/apt.13352..
DOI: 10.1111/apt.13352
Pugliese D., Guidi L., Ferraro P.M., Marzo M., Felice C., Celleno L. et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015; 42(7):880-888. doi: 10.1111/apt.13352..
DOI: 10.1007/s00403-017-1775-7
Melo FJ., Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol. 2018;57(12):1521-1532. doi: 10.1111/ijd.14072..
DOI: 10.1111/ijd.14072
Melo FJ., Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol. 2018;57(12):1521-1532. doi: 10.1111/ijd.14072..
DOI: 10.1007/s00403-017-1775-7
Nidegger A., Mylonas A., Conrad C. Paradoxical psoriasis induced by anti-TNF - a clinical challenge. Rev Med Suisse. 2019;15(644):668-671. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30916904..
DOI: 10.1093/ECC0-0KK/jjv068https://www.ncbi.nlm.nih.gov/pubmed/30916904
Ezzedine K., Visseaux L., Cadiot G., Brixi H., Bernard P, Reguiai Z. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-а agents in patients with inflammatory bowel diseases: A single-center retrospective study. J Dermatol. 2019;46(4):322-327. doi: 10.1111/1346-8138.14816..
DOI: 10.1111/1346-8138.14816
Ezzedine K., Visseaux L., Cadiot G., Brixi H., Bernard P, Reguiai Z. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-а agents in patients with inflammatory bowel diseases: A single-center retrospective study. J Dermatol. 2019;46(4):322-327. doi: 10.1111/1346-8138.14816..
DOI: 10.1093/ECC0-0KK/jjv068
Afzali A., Wheat C.L., Hu J.K., Olerud J.E., Lee S.D. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8(6):480-488. doi: 10.1016/j.crohns.2013.10.013..
DOI: 10.1016/j.crohns.2013.10.013
Afzali A., Wheat C.L., Hu J.K., Olerud J.E., Lee S.D. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8(6):480-488. doi: 10.1016/j.crohns.2013.10.013..
DOI: 10.1159/000500116
Bae J.M., Lee H.H., Lee B.I., Lee K.M., Eun S.H., Cho M.L. et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2018;48(2):196-205. doi: 10.1111/apt.14822..
DOI: 10.1111/apt.14822
Bae J.M., Lee H.H., Lee B.I., Lee K.M., Eun S.H., Cho M.L. et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2018;48(2):196-205. doi: 10.1111/apt.14822..
DOI: 10.1159/000500116
Peer F.C., Miller A., Pavli P., Subramaniam K. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients. Intern Med J. 2017;47(12):1445-1448. doi: 10.1111/imj.13637..
DOI: 10.1111/imj.13637http://www.phdynasty.ru/katalog/zhurnaly/voprosy-prakticheskoy-pediatrii/2015/tom-10-nomer-3/24553
Weizman A.V., Sharma R., Afzal N.M., Xu W., Walsh S., Stempak J.M. et al. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(9):2430-2438. doi: 10.1007/s10620-018-5096-2..
DOI: 10.1007/s10620-018-5096-2http://www.phdynasty.ru/katalog/zhurnaly/voprosy-prakticheskoy-pediatrii/2015/tom-10-nomer-3/24553
Almutairi D., Sheasgreen C., Weizman A., Alavi A. Generalized Pustular Psoriasis Induced by Infliximab in a Patient with Inflammatory Bowel Disease. J Cutan Med Surg. 2018;22(5):507-510. doi: 10.1177/1203475418758986..
DOI: 10.1177/1203475418758986
Almutairi D., Sheasgreen C., Weizman A., Alavi A. Generalized Pustular Psoriasis Induced by Infliximab in a Patient with Inflammatory Bowel Disease. J Cutan Med Surg. 2018;22(5):507-510. doi: 10.1177/1203475418758986..
DOI: 10.18786/2072-0505-2018-46-5-426-444
Eickstaedt J.B., Killpack L., Tung J., Davis D., Hand J.L., Tollefson M.M. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents. Pediatr Dermatol. 2017;34(3):253-260. doi: 10.1111/pde.13081..
DOI: 10.1111/pde.13081
Eickstaedt J.B., Killpack L., Tung J., Davis D., Hand J.L., Tollefson M.M. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents. Pediatr Dermatol. 2017;34(3):253-260. doi: 10.1111/pde.13081..
DOI: 10.18786/2072-0505-2018-46-5-426-444
Udkoff J., Cohen PR. Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn's Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies. Dermatol Ther (Heidelb) 2016;6(4):689-695. doi: 10.1007/s13555-016-0156-z..
DOI: 10.1007/s13555-016-0156-z
Udkoff J., Cohen PR. Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn's Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies. Dermatol Ther (Heidelb) 2016;6(4):689-695. doi: 10.1007/s13555-016-0156-z..
DOI: 10.1080/17474124.2017.1283985
Nissen L.H.C., Pierik M., Derikx L.A.A.P, de Jong E., Kievit W., van den Heuvel T.R.A. et al. Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma. Inflamm Bowel Dis. 2017;23(11):2018-2026. doi: 10.1097/MIB.0000000000001191..
DOI: 10.1097/MIB.0000000000001191
Nissen L.H.C., Pierik M., Derikx L.A.A.P, de Jong E., Kievit W., van den Heuvel T.R.A. et al. Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma. Inflamm Bowel Dis. 2017;23(11):2018-2026. doi: 10.1097/MIB.0000000000001191..
DOI: 10.1080/17474124.2017.1283985
Anderson AJ.M., Ferris L.K., Binion D.G., Smith KJ. Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(10):2564-2572. doi: 10.1007/s10620-018-5141-1..
DOI: 10.1007/s10620-018-5141-1
Anderson AJ.M., Ferris L.K., Binion D.G., Smith KJ. Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(10):2564-2572. doi: 10.1007/s10620-018-5141-1..
DOI: 10.1016/j.dld.2019.03.007
Anderson A., Ferris L.K., Click B., Ramos-Rivers C., Koutroubakis I.E., Hashash J.G. et al. Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci. 2018;63(10):2729-2739. doi: 10.1007Д10620-018-5056-х..
DOI: 10.1007Д10620-018-5056-х
Anderson A., Ferris L.K., Click B., Ramos-Rivers C., Koutroubakis I.E., Hashash J.G. et al. Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci. 2018;63(10):2729-2739. doi: 10.1007Д10620-018-5056-х..
DOI: 10.1016/j.dld.2019.03.007
Hagen J.W., Pugliano-Mauro M.A. Nonmelanoma Skin Cancer Risk in Patients with Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature. Dermatol Surg. 2018;44(4):469-480. doi: 10.1097/dss.0000000000001455..
DOI: 10.1097/dss.0000000000001455
Hagen J.W., Pugliano-Mauro M.A. Nonmelanoma Skin Cancer Risk in Patients with Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature. Dermatol Surg. 2018;44(4):469-480. doi: 10.1097/dss.0000000000001455..
DOI: 10.1016/j.ad.2016.07.007